Clinical Trial: Exercise and Body Composition in Juvenile Idiopathic Arthritis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: "Joint Fitness": A Double-Armed Controlled Intervention to Assess the Safety and Effectiveness of Resistance Exercise Training on Muscle, Bone, Strength, Symptoms, Quality of Life and Biolog

Brief Summary:

This research is being done to see if resistance exercise (RE) is safe and has a positive effect on children and young adults with juvenile idiopathic arthritis (JIA).

JIA is an inflammatory autoimmune disease that can cause severe impairment and disability. JIA can cause bone loss and decreased muscle strength. The medications used to treat JIA can also have negative effects on growth and development, strength, and ability to function. RE is performing movements in a slow and controlled fashion (i.e., no speeding up or using force in the lifting and lowering of the weight) to lessen force on the joints and tissues. This study will be using Ren-Ex exercise equipment to perform RE.

Currently the American College of Rheumatology recommends exercise for patients with arthritis. This exercise includes range of motion exercise to protect joint mobility as well as low resistance and aerobic exercise (AE) to protect muscle mass, bone health, and fitness. However, a recent study showed no major differences in functionality or quality of life between patients who performed AE and those who did not perform AE. There is a need for more data on the impact of RE on children with JIA. Children and young adults aged 10 to 21 with juvenile idiopathic arthritis may join.


Detailed Summary:
Sponsor: Johns Hopkins University

Current Primary Outcome:

  • Change in Total Body Dual-Emission X-ray Absorptiometry (DEXA) Scan [ Time Frame: Baseline and 12 weeks ]
    Total and lean body mass and fat mass will be determined
  • Change in BMI [ Time Frame: Baseline and 12 weeks ]
  • Change in Lower and upper extremity strength testing [ Time Frame: Baseline and 12 weeks ]
    Isokinetic strength testing with a Biodex dynamometer to measure peak torque


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Baseline and 12 weeks ]
  • Change in Erythrocyte sedimentation rate (ESR) [ Time Frame: Baseline and 12 weeks ]
  • Change in Quality of Life [ Time Frame: Baseline and 12 weeks ]
    Questionnaire administration
  • Change in C-reactive protein (CRP) [ Time Frame: Baseline and 12 weeks ]


Original Secondary Outcome: Same as current

Information By: Johns Hopkins University

Dates:
Date Received: May 1, 2015
Date Started: July 2012
Date Completion:
Last Updated: June 19, 2015
Last Verified: June 2015